Improved myocardial recovery after cardioplegic arrest with an oxygenated crystalloid solution.
Possible enhancement of myocardial protection by oxygenation of a crystalloid cardioplegic solution was evaluated in a three-part study. In Part I, canine hearts underwent ischemia followed by heterogeneous cardioplegic arrest for 45 to 60 minutes. Oxygenation led to improved recovery in the left anterior descending region (47% versus 86% recovery, p less than 0.05) (15 minutes of ischemia) and in the circumflex region (9.5% versus 52% recovery, p less than 0.05) (30 minutes of ischemia). Part II was a blind prospective randomized study in 12 patients. It examined creatine kinase, myoglobin, and lactate as well as coronary sinus flow, oxygen consumption, and cardiac work 1 hour after aortic cross-clamping during atrial and during ventricular pacing. No significant difference was demonstrable between control and oxygenated solutions. In Part III, 57 coronary bypass patients were protected with a nonoxygenated solution while 94 patients received an identical oxygenated solution. Twelve-hour creatine kinase levels were similar in the nonoxygenated (9.5 +/- 16 IU, +/- standard deviation) and oxygenated (11 +/- 22 IU) groups if the cross-clamp interval was 28 minutes or less. In patients subjected to longer than 28 minutes of arrest, the 12 hour creatine kinase MB levels were more than twice as high in the nonoxygenated group (26.5 +/- 26 IU) compared to the oxygenated group (9.9 +/- 14 IU, p less than 0.05). In this canine model of heterogeneous cardioplegia and in the routine conduct of coronary bypass operations, oxygenated crystalloid cardioplegia is superior to an identical nonoxygenated solution.
D000818:Animals; D001026:Coronary Artery Bypass; D003402:Creatine Kinase / Q000097:blood; D004285:Dogs; D004562:Electrocardiography; D006324:Heart Arrest, Induced; D006801:Humans; D006982:Hypertonic Solutions; D007527:Isoenzymes; D010100:Oxygen; D011184:Postoperative Period; D011188:Potassium; D017680:Potassium Compounds; D011446:Prospective Studies; D011897:Random Allocation; D012189:Retrospective Studies; D013997:Time Factors
D006982:Hypertonic Solutions; D007527:Isoenzymes; D017680:Potassium Compounds; C018369:potassium cardioplegic solution; D003402:Creatine Kinase; D011188:Potassium; D010100:Oxygen